Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study
BioFactors · 2024
DOI: 10.1002/biof.2041 ↗Kurz gefasst
Fachartikel in der Zeitschrift BioFactors, 2024. Verfasst von Laura Guerrero und 8 weiteren Autor:innen. Beteiligte Einrichtung: Functional Proteomics Labortory, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain. Hauptthemen laut MEDLINE: Cholestasis, Intrahepatic, Proteomics, ATP Binding Cassette Transporter, Subfamily B. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Centro Nacional de Biotecnología, Ministerio de Ciencia e Innovación, Comunidad de Madrid.
Abstract (Originalsprache)
Progressive familial intrahepatic cholestasis type 3 (PFIC3) is a severe rare liver disease that affects between 1/50,000 and 1/100,000 children. In physiological conditions, bile is produced by the liver and stored in the gallbladder, and then it flows to the small intestine to play its role in fat digestion. To prevent tissue damage, bile acids (BAs) are kept in phospholipid micelles. Mutations in phosphatidyl choline transporter ABCB4 ( MDR3 ) lead to intrahepatic accumulation of free BAs that result in liver damage. PFIC3 onset usually occurs at early ages, progresses rapidly, and the prognosis is poor. Currently, besides the palliative use of ursodeoxycholate, the only available treatment for this disease is liver transplantation, which is really challenging for short‐aged patients. To gain insight into the pathogenesis of PFIC3 we have performed an integrated proteomics and phosphoproteomics study in human liver samples to then validate the emerging functional hypotheses in a PFIC3 murine model. We identified 6246 protein groups, 324 proteins among them showing differential expression between control and PFIC3. The phosphoproteomic analysis allowed the identification of 5090 phosphopeptides, from which 215 corresponding to 157 protein groups, were differentially phosphorylated in PFIC3, including MDR3. Regulation of essential cellular processes and structures, such as inflammation, metabolic reprogramming, cytoskeleton and extracellular matrix remodeling, and cell proliferation, were identified as the main drivers of the disease. Our results provide a strong molecular background that significantly contributes to a better understanding of PFIC3 and provides new concepts that might prove useful in the clinical management of patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Functional Proteomics Labortory, Centro Nacional de Biotecnología (CNB-CSIC), Madrid, Spain.
- IdiPAZ, Instituto de Investigación Sanitaria [Health Research Institute] of Hospital Universitario La Paz, Madrid, Spain.
- Servicio de Anatomía Patológica, Hospital Universitario La Paz, Madrid, Spain.
ORCID-Profile: Laura Guerrero, Lorena Carmona-Rodríguez, Fernando J Corrales
Förderung
- Centro Nacional de Biotecnología
- Ministerio de Ciencia e Innovación
- Comunidad de Madrid
- European Commission-NextGenerationEU
Zitieren
APA
Guerrero, L., Carmona-Rodríguez, L., Santos, F. M., Ciordia, S., Stark, L., Hierro, L., Pérez-Montero, P., Vicent, D., & Corrales, F. J. (2024). Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study. BioFactors. https://doi.org/10.1002/biof.2041
Vancouver
Guerrero L, Carmona-Rodríguez L, Santos FM, Ciordia S, Stark L, Hierro L, et al. Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study. BioFactors. 2024. doi:10.1002/biof.2041
BibTeX
@article{Guerrero2024,
author = {Guerrero, Laura and Carmona-Rodríguez, Lorena and Santos, Fátima Milhano and Ciordia, Sergio and Stark, Luiz and Hierro, Loreto and Pérez-Montero, Pablo and Vicent, David and Corrales, Fernando J},
title = {Molecular basis of progressive familial intrahepatic cholestasis 3. A proteomics study},
journal = {BioFactors},
year = {2024},
doi = {10.1002/biof.2041}
}
EUVIMED